Results 71 to 80 of about 44,651 (208)
Brazilian Journal of Infectious DiseasesPeginterferon alfa plus ribavirin is currently the treatment of choice for chronic hepatitis C. Peginterferon alfa-2a (40KD) plus ribavirin has given an overall sustained virological response of 18% in F3/F4 previous nonresponder US patients.
E. Parise +16 more
doaj +1 more source
Annals of Hepatology, 2012 Introduction. A large number of patients with chronic hepatitis C have not been cured with interferon-based therapy. Therefore, we evaluated the efficacy of amantadine combined with the standard of care (pegylated interferon plus ribavirin) in patients ...
Mario G. Pessôa +12 more
doaj +1 more source
Journal of Infection in Developing Countries, 2011 Interferon alpha is a molecule frequently used in the treatment of chronic hepatitis B, C, and D, with immunomodulatory and antiviral activity. It is also used in some cancer types. It has been widely claimed that interferon alpha triggers autoimmunity,
Sukran Kose +3 more
doaj +1 more source
Acta Gastroenterológica Latinoamericana, 2009 Introducción. El tratamiento recomendado para los pacientes con hepatitis B crónica HBeAg positivo es PEG interferón alfa 2a durante 48 semanas. No hay suficientes datos que avalen mejor respuesta con 48 semanas de tratamiento versus 24 semanas.
Joaquín Solari +9 more
doaj
Annals of Hepatology, 2010 There are no well established treatment guidelines about acute hepatitis C (AHC), leaving physicians to make several challenging decisions, such whether to treat, when to treat and what treatment regimens to use.
Paulo Roberto Lerias de Almeida
doaj +1 more source
Plasma N-Terminal Pro-Brain Natriuretic Peptide as Prognostic Marker in Fatal Cardial Decompensation with Sunitinib Malate Therapy [PDF]
, 2010 A 74-year-old man with metastatic renal cell carcinoma and a history of cardiac failure was treated with sunitinib malate. MUGA echocardiography could not detect a relevant change in the ejection fraction although the clinical situation of the patient ...
Haseke, Nicolas +4 more
core +1 more source
Effectiveness and tolerability of pegylated interferon alfa-2b in combination with ribavirin for treatment of chronic hepatitis C: the PegIntrust Study [PDF]
, 2010 Background and study aims : Large international clinical trials conducted in the past 5 years rapidly improved the treatment of chronic hepatitis C; however, it is unclear whether the advances seen in clinical trials are being paralleled by similar ...
Adler, M +14 more
core +2 more sources
Raised serum transaminases during treatment with pegylated interferon for chronic hepatiti C [PDF]
, 2016 Introduction : Serum transaminases rose significantly in 7 patients with chronic hepatitis C, genotypes 2 and 3, who were treated with pegylated interferon and ribavirin. Methods : 219 patients with chronic hepatitis C, genotypes 2 and 3, were treated
Datta, S. +3 more
core +1 more source
A cost-utility analysis of different antiviral medicine regimens in patients with chronic hepatitis C virus genotype 1 infection [PDF]
, 2016 Background: Despite the introduction of new drug regimens with high effectiveness for the hepatitis C virus (HCV) patients, especially in HCV genotype 1, no cost-effectiveness study on the selection of the superior drug strategy in Iran has been ...
Alavian, Seyed Moayed +6 more
core +1 more source
Systemic Interferon Alfa in Multiple Sclerosis
Archives of Neurology, 1989 To the Editor. —We wish to comment on the conclusions reached by Panitch 1 in his follow-up study of patients treated with subcutaneous interferon alfa. Panitch notes that patients treated with interferon alfa experienced a reduction in attack frequency from 1.33 per year to 0.47 per year over a mean follow-up of four years.
Weinshenker, BG, Ebers, G
openaire +2 more sources